CD274 and neoplasm: Immunotherapies targeting the PD-1/PDL-1 pathway have surpassed the 10% response rate ceiling typically associated with other immunotherapies [4], though they are subject to limitations imposed by a patient’s specific immune system and tumor microenvironment.